CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.

CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.

Cutaneous leishmaniasis (CL) affects the lives of 0.7-1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first line of therapy for CL, however the treatment is l...

Full description

Bibliographic Details
Main Authors: Seth G Thacker, Ian L McWilliams, Beatrice Bonnet, Lydia Halie, Serge Beaucage, Swaksha Rachuri, Ranadhir Dey, Robert Duncan, Farrokh Modabber, Stephen Robinson, Graeme Bilbe, Byron Arana, Daniela Verthelyi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-02-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0008050

Internet

https://doi.org/10.1371/journal.pntd.0008050

Similar Items